Maintaining integrity of gut membrane (and basement membrane) to reduce microplastic exposure

#1

Mike lustgarten had an early book on LPS levels leaking into the blood!
And maintaining the right microbiome like the 117 year old centenarian could be the way to reducing microplastic absorption by maintaining gut barrier integrity

Maybe some kinds of fiber when balanced out

===

https://www.sciencedirect.com/science/article/pii/S2590006425009329

LPL secreted by adipocytes, myocytes, and other parenchymal cells is shuttled to the glycocalyx of the capillary endothelial cells by the chaperone protein GPIHBP1 (11, 15, 16). GPIHBP1-bound LPL then hydrolyses triglycerides within the core of the circulating TRLs into free fatty acids and glycerol

https://x.com/pia_burboa/status/1587530911813455879
https://www.jci.org/articles/view/198352/figure/1

#2

Short answer: possibly — but the evidence is very preliminary. Don’t dump your food filters just yet.

Here’s what the science says (with me grumbling in the margins):

What’s the idea behind “probiotics reducing microplastic uptake”?

Microplastics (MPs) — tiny bits of plastic under ~5 mm — can get into your gut via food, water, air, etc. (PMC) Some studies (mostly in animal models) suggest MPs may:

  • Disrupt gut barrier integrity (“leaky gut”) (MDPI)
  • Trigger inflammation and oxidative stress (MDPI)
  • Cause gut microbiome imbalance (dysbiosis) (BioMed Central)

If your gut barrier is intact, it’s harder for stray particles to cross into your bloodstream or deeper tissues. So the hypothesis is: if probiotics help strengthen or repair the gut barrier, reduce inflammation, and maintain microbiome balance, they might indirectly reduce how many microplastics “leak” through or cause harm.

Some additional speculative (and initial) mechanisms:

  • Probiotics might bind or adsorb microplastics in the gut lumen, helping them be excreted rather than sticking to the mucus or epithelium. (Frontiers)
  • They might stimulate mucus production, reinforce tight junctions between gut cells, or modulate immune responses to repair damage. (PMC)

One recent paper: in a mouse model, certain probiotic strains (Lacticaseibacillus paracasei DT66 and Lactiplantibacillus plantarum DT88) showed improved excretion of polystyrene microplastics and reduction of residual particles in the gut. (Frontiers) That is intriguing — but mice ≠ humans (yes, I’m forced to point that out).

What we don’t know (yet) — the caveats

  • Human evidence is very scarce. Most studies are in vitro (cells), or in animals. (PMC)
  • We don’t know which strains, dosages, or durations (if any) are effective in humans.
  • The binding/adsorption capacity is likely very limited (i.e., probiotics won’t “soak up” all microplastics you ingest).
  • Microplastics vary a lot in size, chemical composition, and surface coatings — what works on one kind may not work on another. (Taylor & Francis Online)
  • Strengthening the gut barrier is just one line of defense. Even with perfect barrier function, some very small particles might still pass (especially nanoparticles).
  • The probiotic approach doesn’t address the root problem: ingesting less microplastic in the first place (e.g. via better food packaging, filtration, environmental change, etc.).

My estimate (yes, I’m forced to hazard a guess)

Probiotics could reduce microplastic uptake somewhat by maintaining or repairing gut integrity and promoting excretion of particles that otherwise might linger or embed. But it’s very unlikely to be a “silver bullet” — you’d still be exposed, and the reduction might be modest.

If you like, I can look up the most promising probiotic strains (in humans) and estimate how much effect they might have (with big error bars). Do you want me to dig that?

Short answer: probably a small-to-moderate dent, not a force field. If I had to put numbers on it anyway (and you did ask), here’s a sober, back-of-envelope estimate with the best current evidence and a painful amount of honesty:

My estimate (with assumptions spelled out)

  • Human translocation of MPs ≥0.1–10 µm: probiotics that improve barrier integrity likely cut gut-to-tissue passage by about 10–25% after 4–12 weeks. That range is inferred from RCT/meta-analytic signals that probiotics lower permeability markers (e.g., zonulin) and bolster tight junctions/TEER, not from direct MP trials in humans. (Frontiers)
  • Nanoplastics (<0.1 µm): more slippery, less influenced by mucus and tight junction tweaks. I’d only expect 0–10% reduction in translocation, if any, from probiotics alone. Mechanistic reviews basically warn this size class is harder to block. (PMC)
  • “Binding/flush-out” effect in vivo: in mice, two screened strains (Lacticaseibacillus paracasei DT66 and Lactiplantibacillus plantarum DT88) boosted fecal excretion of 0.1-µm polystyrene by ~34% and cut residual intestinal load by up to ~67%. If a human analog pans out, I’d conservatively project ~15–35% more excretion and ~20–40% less residual intestinal MP short-term. This is extrapolation; the only hard numbers are from the mouse paper. (Frontiers)

What supports those numbers

  • A mouse study directly screening 784 strains found DT66/DT88 aggregated MPs and meaningfully increased excretion while reducing gut residues. That’s the strongest “removal” signal so far, but it’s not a human trial. (Frontiers)
  • Multiple reviews/RCTs show probiotics can tighten the epithelial barrier and lower permeability markers in humans, which should reduce passive particle leak. But they track proxies like zonulin, TEER, or endotoxin/LPS, not MPs themselves. Effect sizes are real but moderate. (Frontiers)
  • Mechanistic and narrative reviews agree MPs disrupt barrier function and cause inflammation. Fixing the barrier plausibly reduces MP uptake, just don’t expect miracles, especially for nano-range particles. (PMC)

Strains and tactics that are plausibly useful

  • Barrier-centric strains: multi-strain lactobacilli/bifido blends that improved TEER/tight-junction proteins in trials; typical dosing 10⁹–10¹⁰ CFU/day for 8–12 weeks. (MDPI)
  • Akkermansia muciniphila or next-gen formulas that thicken mucus and lower permeability. Human data are still thin, but it’s the poster microbe for barrier tone. (PMC)
  • Targeted binders: if DT66/DT88 ever hit shelves with real human data, that’s your “excrete more plastic, leave less behind” option. For now, they’re proof-of-concept in animals, not a shopping list. (Frontiers)

Reality check

  • There are no human RCTs showing probiotics measurably reduce microplastic body burden. All human-ish numbers above are inferred from barrier improvements and mouse MP-excretion data. If someone sells you a “microplastic detox probiotic” with precise human percentages, they’re selling vibes. (PMC)

Bottom line for an actually useful plan

  • Expect modest help from probiotics: think ~10–25% less uptake for larger MPs via barrier support, and maybe noticeable excretion gains if DT66/DT88-like strains translate.
  • Stack with exposure control for real gains: filtered water, avoid heating food in plastic, fewer plastic-shedding textiles, etc. Reviews keep repeating this because it’s the only lever with big effect sizes right now. (The Guardian)

Grim, but not hopeless. Your gut can be part bouncer, just not a hazmat team.

#3

Good question. I poked around. Here’s what I found — and why “finding DT66 / DT88 at your local supplement store” is unlikely (sorry).

What is DT66 / DT88

  • These are experimental probiotic strains (i.e. specific isolates) identified in a recent study for their ability to adsorb microplastics. (PMC)
  • They are not (yet) commercialized or incorporated into consumer probiotic products — at least not in publicly documented form.
  • The original paper reports their performance in vitro and in mice, but doesn’t mention that they’ve been deposited in major culture collections with certifications for human use. (PubMed)
  • If you see strains labeled “DT66” or “DT88” in a supplement, be skeptical — they could be mislabeling, or preliminary.

Where you would look, if they become available

If someone does commercialize them (or make them available to researchers), here are the typical routes:

  1. Microbial culture collections / strain banks
    e.g. ATCC, DSMZ, NCIMB, etc. Researchers deposit novel strains there. You could check whether DT66 or DT88 are listed in any of these.
    (So far, I did not find DT66 or DT88 in ATCC / DSMZ in the sources I checked.)

  2. Academic collaboration / research labs
    Contact the authors of the paper. They might share strains for research or partner with a biotech company.

  3. Niche probiotic or “next-gen probiotics” companies
    If a biotech startup picks up DT66/DT88, they might incorporate into a future product, but that would require regulatory approval, safety checks, etc.

  4. Patent filings
    Sometimes strains are patented. If the DT66 or DT88 strain is patented, licensing might be required before commercialization. I didn’t see a direct patent for DT66/DT88 in my search, but that doesn’t mean there isn’t one.

  5. Clinical trials
    If someone runs a human trial, they might make the probiotic available (to participants) via trial registration. You could check clinicaltrials.gov or local university trial registries.

My verdict (saddest moment of the day)

You won’t reliably find DT66 or DT88 in off-the-shelf probiotic capsules or yogurts at present. They are research strains, still in the “potential future probiotic” stage. If you want, I can try to dig whether any biotech is planning to commercialize them, or check culture collections more deeply (for you). Do you want me to do that?

#4

Short, slightly depressing answer: bowhead whales almost certainly ingest far more micro/nanoplastics than people do, by orders of magnitude. But when you zoom into concentrations inside guts/tissues, the few bowhead data points we have land in the same ballpark as humans and sometimes lower than human extremes. Different units and methods make clean head-to-head bragging rights impossible, which is very on brand for environmental science.

What’s actually measured

  • Ingestion rate: Baleen whales (the club bowheads belong to) hoover up prey and, with it, plastics. Field-based estimates for blue/fin/humpback show ~0.2–10 million microplastic pieces per day depending on species and diet. Bowheads weren’t directly in those California datasets, but the feeding mode is the same, so they’re plausibly in that neighborhood when prey is contaminated. (PMC)

  • Bowhead concentrations (tissues): A 2025 UAF analysis of subsistence-harvested bowheads reported microplastics in every sampled tissue with approximate means of ~7.9 MP/g in stomach contents, ~17 MP/g in colon contents, ~6.8 MP/g in muscle. That’s particles per gram, not mass. Early days, small sample, but it’s the best bowhead-specific number we’ve got. (University of Alaska Fairbanks)

  • Human benchmarks:

    • Stool: recent human studies find medians around ~3.5–6.5 MP/g feces, with ranges that can run much higher in some cohorts. So your gut can match a whale’s colon on a good (bad) day. (PubMed)
    • Blood: measured as mass concentration, not counts: roughly ~1–5 µg/mL total polymer across studies. Different unit, same “ugh.” (Vrije Universiteit Amsterdam)
    • Placenta: studies report ~6.5–790 µg/g tissue, again mass-based and method-dependent, which can dwarf anything we’ve converted for whales so far just because it’s a different metric. (UNM HSC Newsroom)

So… higher or lower?

  • Daily intake: bowheads ≫ humans. A filter-feeding whale is basically a Roomba with a PhD in krill. You are not. (PMC)
  • Per-gram tissue/gut levels: overlap. Bowhead colon/stomach values in particles per gram sit near human stool medians and below the highest human reports. Cross-species comparisons wobble because labs use different size cutoffs, dyes, and units. (University of Alaska Fairbanks)

If you’re looking for a headline: whales take in way more; humans may carry similar or higher concentrations in some tissues depending on how you measure. Science will eventually standardize methods, right after we standardize literally everything else humans can’t agree on.

#5

“But probiotics are often dead or don’t survive digestion…” As shocking as it sounds, even dead probiotics are still beneficial! This is due to their cell wall components (ie lipoteichoic acids, peptidoglycans, or exopolysaccharides) that modulate the immune system and gut barrier integrity 1:31 PM · Apr 18, 2026 · 1,881 Views Relevant Bryce Hanna @photobiogenesis · 2h Both live and dead probiotics can: - reduce intestinal inflammation - improve gut barrier integrity - reduce inflammatory response to endotoxin - anti-allergic effects - improve glucose control - upregulate the immune function Dead probiotics cannot: - colonize the gut - enter Show more Bryce Hanna @photobiogenesis · 2h While I’ve often spoken about TLR4 in the context of endotoxin-induced inflammation, some of the effects of dead probiotics are mediated via another receptor in the same family called TLR2 Among other effects TLR2 increases endothelial resistance to bacterial invasion Bryce Hanna @photobiogenesis ·

#6

Yes, possibly, but very strain-specifically. The interesting part is that this has moved beyond pure test-tube speculation in 2026.

The species is now formally called Lactiplantibacillus plantarum. Certain strains can physically bind micro/nanoplastics in the gut, forming bacteria-plastic aggregates that are more readily carried out in feces. They may also tighten the intestinal barrier, potentially reducing translocation of smaller particles. (PubMed Central (PMC))

The evidence ladder currently looks like this:

  • DT88: in mice, treatment increased polystyrene excretion by about 34% and reduced residual intestinal polystyrene by roughly 67%. (PubMed Central (PMC))
  • PD01: isolated from a human who naturally excreted relatively high amounts of microplastics. In mice, it reduced intestinal retention of PVC by 67%, PET by 56%, PS by 91%, and PE by 50%. (Nature)
  • ZP-6: mouse experiments suggest enhanced fecal excretion and reduced nanoplastic retention in blood/tissues, with improved intestinal barrier function. (Frontiers)
  • Most interestingly, an August 2026 randomized double-blind human trial preprint tested PD01 for six weeks. The intervention used 10¹⁰ CFU after each meal, three times daily. Urinary metabolites of several plasticizers fell about 36–60% versus placebo. However, the preprint calls these interim results and says the actual microplastic-particle analyses were not yet the completed analysis being reported. So I would not yet say that PD01 has been demonstrated to remove 50% or 90% of microplastics from humans. (MedRxiv)

How to increase L. plantarum

The most predictable method is actually consuming a known strain, rather than trying to coax your existing microbiome into producing more of it. L. plantarum probiotics substantially raise fecal lactobacilli while they’re being consumed, but levels can fall again after supplementation stops, so they’re often transient passengers rather than permanent residents. (PubMed)

For food sources, look for refrigerated, unpasteurized, live-fermented plant foods, especially sauerkraut, kimchi, brine-fermented olives, and genuinely fermented pickles. L. plantarum is common in fermented foods, including kimchi and olives. The problem is that the strain and dose are unpredictable. (PubMed)

A probiotic that merely says “L. plantarum” is better defined, but for your specific MNP goal I’d want the strain ID printed on the product. This matters a lot. A 2025 review found major differences among L. plantarum strains across clinical effects, and the plastic-binding experiments similarly found high-binding and low-binding L. plantarum strains. (PubMed Central (PMC))

So something like 299v can certainly increase L. plantarum exposure, and it has substantial human safety/clinical data, but there is currently no good evidence that 299v has the same MNP-binding phenotype as PD01, DT88, or ZP-6. I wouldn’t treat all plantarum strains as interchangeable microscopic plastic vacuum cleaners. :microbe::magnet:

There also isn’t convincing evidence that a particular prebiotic selectively expands your native L. plantarum. General fermentable fiber can support a healthier fermentation ecology, but that is different from deliberately increasing this species. Interestingly, the PD01 human trial gave FOS to both the PD01 and placebo groups, so the reported between-group effect cannot simply be attributed to FOS. (MedRxiv)

For the MNP-clearing goal specifically, I’d rank the approaches: obtaining the actual PD01 strain if/when it becomes legitimately available > another experimentally high-binding strain such as DT88 > generic L. plantarum supplement > live fermented foods > trying to manipulate it indirectly with prebiotics.

And the important counterpoint: these probiotics are most plausibly useful for MNPs passing through the intestine and preventing further absorption. We do not yet have solid evidence that taking L. plantarum can pull long-deposited nanoplastics out of the human brain, vasculature, liver, etc. That’s a much bigger biological claim than increasing fecal elimination of newly ingested particles. (MedRxiv)

If you want, I can also track down whether PD01, DT88, or ZP-6 are actually obtainable as probiotics right now, versus strains that currently exist only in research collections.